Journal of Medical and Surgical
Research (JMSR)


Pages: 1142-1144DOI: 10.46327/msrjg.1.000000000000229

Date of Publication: 30-Nov--0001

IgD Multiple Myeloma Complicated of Acquired Factor XI Deficiency: A Case Report

Author: Noufissa Alami Drideb, Sanae Bouchnafati, Saloua Saoudi, Hajar Masrour, Maha Ouazzani, Naoual Oubelkacem, Mounia Bouzayd, Zineb Khammar, Rhizlane Berrady

Category: JMSR Oncology

[Download PDF]


IgD multiple myeloma (MM) is a rare isotype of multiple myeloma, comprising less than 2% of all cases. IgD myeloma characterized by aggressive presentation and shorter overall survival than other subtypes of MM. Acquired deficiency of coagulation factor can complicate hematological malignancies; bleeding depends on level and on the factor deficiency. Factor XI deficiency is relatively low risk spontaneous bleeding. There are few cases of IgD MM described in the literature especially complicated with factor deficiency. We report a rare case of IgD lambda multiple myeloma with acquired factor XI deficiency.

Keywords: Case report, IgD myeloma, Factor XI deficiency, Multiple myeloma


  1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S et al. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. Lancet Oncol 2014;15: e538–48. [PubMed: 25439696]
  2. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404
  3. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W: IgD multiple myeloma: review of 133 cases. Arch Intern Med. 1975, 135:87-93
  4. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, S R Hayman , Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–8. [PubMed: 24157580]
  5. Reynolds SB, Maghavani DP, Hashmi H. Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for anti-myeloma therapy for bleeding diathesis. BMJ Case Rep. 2019 Sep 16; 12 (9): e230249.
  6. Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol 2016;9(07):629–637
  7. Goodrick MJ, Prentice AG, Copplestone JA, Pamphilon DH, Boon RJ. Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J Clin Pathol 1992;45(04):352–353
  8. Despina S Kyriakou , Michael G Alexandrakis, Freda H Passam, Kalliopi Foundouli, Emmanouel Matalliotakis, Ioannis E Koutroubakis, Taxiarchis V Kourelis, George Chalkiadakis, Orestis N Manoussos. Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol 2002; 14 (12): 1383–1387
  9. Jethava Y, Alamelu J, Rangarajan S, Lang-Lazdunski L, van der Walt J, Fields P. Acquired agranulocytosis and factor XI deficiency in association with thymoma. J Clin Oncol 2011;29 (20): e604–e606
  10. S. Vincent Rajkumar, M.D. Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management. Am J Hematol. 2022; 97 (8): 1086–1107. doi:10.1002/ajh.26590
  11. Jin Liu, Xiaoxia Hu, Yanchun Jia, Jin Lu, Jae Hoon Lee, Kihyun Kim, Wenming Chen, Aijun Liu,Yang Liu, Qi Chen, Chunyang Zhang, Cheolwon Suh, Min Kyoung Kim, Fan Zhou, Wee Joo Chng, Shaji K. Kumar, Brian Durie, Jian Hou, Weijun Fu,Juan Du: Clinical features and survival outcomes in IgD myeloma: A study by Asia Myeloma Network (AMN). Leukemia. 2021, 35: 1797- 802. doi: 10.1038/s41375-020-01060-w